Study S001678

A Phase 1, Open-label, Randomized, Parallel Group Study to Assess the Relative Bioavailability of Maridebart Cafraglutide (AMG 133) as Two Subcutaneous Presentations in Participants Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07313761
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 349
Start: 2025-12-15
Primary completion: 2026-07-02
Lead sponsor: Amgen
Conditions: Overweight and Obesity
Interventions: DRUG:Maridebart Cafraglutide
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Area Under the Plasma Concentration-time Curve (AUC) From Time 0 to Infinity (AUCinf) of AMG 133 [Up to Day 120]
AUC From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of AMG 133 [Up to Day 120]
Maximum Observed Plasma Concentration (Cmax) of AMG 133 [Up to Day 120]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.